INC Research (INCR) – Investment Analysts’ Recent Ratings Updates

INC Research (NASDAQ: INCR) has recently received a number of price target changes and ratings updates:

  • 1/4/2018 – INC Research had its “buy” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $52.00 price target on the stock.
  • 1/4/2018 – INC Research had its “buy” rating reaffirmed by analysts at KeyCorp. They now have a $50.00 price target on the stock.
  • 1/3/2018 – INC Research was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 12/18/2017 – INC Research was downgraded by analysts at TheStreet from a “b-” rating to a “c” rating.
  • 12/11/2017 – INC Research is now covered by analysts at Barclays PLC. They set an “equal weight” rating and a $40.00 price target on the stock.
  • 12/7/2017 – INC Research was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 12/1/2017 – INC Research had its price target lowered by analysts at SunTrust Banks, Inc. to $50.00. They now have a “buy” rating on the stock.
  • 12/1/2017 – INC Research was given a new $41.00 price target on by analysts at Mizuho. They now have a “neutral” rating on the stock.
  • 11/16/2017 – INC Research was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong sell” rating. According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
  • 11/16/2017 – INC Research was given a new $46.00 price target on by analysts at Robert W. Baird. They now have a “buy” rating on the stock.
  • 11/14/2017 – INC Research had its price target lowered by analysts at Credit Suisse Group AG from $68.00 to $54.00. They now have an “outperform” rating on the stock.
  • 11/13/2017 – INC Research had its “market perform” rating reaffirmed by analysts at KeyCorp. They now have a $46.00 price target on the stock, down previously from $68.00.
  • 11/10/2017 – INC Research had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $55.00 price target on the stock.
  • 11/10/2017 – INC Research was downgraded by analysts at Robert W. Baird to an “outperform” rating. They now have a $46.00 price target on the stock, down previously from $67.00.

INC Research Holdings Inc (INCR) traded down $0.80 during mid-day trading on Monday, hitting $40.50. 1,484,300 shares of the stock were exchanged, compared to its average volume of 1,285,400. INC Research Holdings Inc has a twelve month low of $33.60 and a twelve month high of $61.10. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.27 and a quick ratio of 1.27. The firm has a market capitalization of $4,230.00, a P/E ratio of -69.83, a P/E/G ratio of 1.25 and a beta of 1.09.

INC Research (NASDAQ:INCR) last released its quarterly earnings results on Thursday, November 9th. The company reported $0.54 earnings per share for the quarter, missing analysts’ consensus estimates of $0.63 by ($0.09). INC Research had a positive return on equity of 14.42% and a negative net margin of 4.29%. The company had revenue of $592.21 million for the quarter, compared to analyst estimates of $604.95 million. During the same period in the previous year, the business posted $0.64 EPS. The firm’s quarterly revenue was up 128.2% compared to the same quarter last year. research analysts forecast that INC Research Holdings Inc will post 2.15 EPS for the current fiscal year.

INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.

What are top analysts saying about INC Research Holdings Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for INC Research Holdings Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit